Malek joins NIBR as head of oncology disease area
Plus: Translate Bio vet Smith joins CRISPR as CFO and updates from Travere, Kojin, AMO, Poseida, Synairgen and more
After more than 15 years at Genentech Inc., Shiva Malek has left the Roche (SIX:ROG; OTCQX:RHHBY) unit to lead the oncology disease area at Novartis Institutes for BioMedical Research, the innovation “engine” of Novartis AG (SIX:NOVN; NYSE:NVS). Malek joined Genentech in 2006 as a scientist, rising through the ranks to become VP of discovery oncology and helping to build the company’s small molecule drug discovery team. Before Genentech, Malek was a scientist at Exelixis Inc. (NASDAQ:EXEL) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).
Brendan Smith became CFO at CRISPR Therapeutics AG (NASDAQ:CRSP), succeeding Michael Tomsicek, who is retiring. Smith was most recently CFO, corporate strategy at Translate Bio Inc., which was acquired by Sanofi (Euronext:SAN; NASDAQ:SNY)...